Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 28
  1. Apr 27, 2026 · 09:00 · VVTM · Routine +

    VVT Med Secures European Distribution Amid Regulatory Overhang

    VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor

    01
  2. Apr 27, 2026 · 09:00 · TSXV: · Routine +

    VVT Med Secures Italian Distribution with Investor Participation, Incremental Revenue Stream Established

    VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor

    02
  3. Apr 27, 2026 · 08:01 · BIOV · Neutral

    BioVaxys Shares Plunge Amid Compliance Risks Despite ASCO Presentation

    BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

    03
  4. Apr 27, 2026 · 07:30 · BCT · Routine +

    BriaCell Announces ASCO 2026 Data Presentations Amidst Dilution Concerns and Phase 3 Readout Wait

    BriaCell Announces Six Clinical Data Presentations at ASCO 2026

    04
  5. Apr 27, 2026 · 07:00 · MBX · Neutral

    Microbix Product Validation Fails to Offset Revenue Decline and Cash Burn Concerns

    Microbix Product Results Being Presented at 2026 PASCV

    05
  6. Apr 27, 2026 · 07:00 · SONA · Routine +

    Clinical Data Validation

    Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

    06
  7. Apr 24, 2026 · 16:49 · OPEN · Routine +

    RTO Completion Secures Capital but Implies Significant Valuation Reset for Existing Shareholders

    Opensesame closes qualifying transaction

    07
  8. Apr 24, 2026 · 16:42 · MYTC · Material −

    MyndTec Bankruptcy Filing Confirms Total Equity Wipeout After Financing Collapse

    MyndTec Inc. Makes Voluntary Assignment in Bankruptcy Under the Bankruptcy and Insolvency Act (Canada)

    08
  9. Apr 24, 2026 · 13:02 · PAIN · Routine +

    Vector Science RTO Raises $2.3M Amidst Biotech Device Ambitions

    Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

    09
  10. Apr 24, 2026 · 08:01 · SURE · Routine +

    SureNano Advances GLP-1 Pipeline Amidst Marketing Spend and Dilution Concerns

    SureNano Science Initiates FDA Stage GLP Toxicology and Pharmacology Studies for GLP GEP-44 and Enters Discussions to Acquire Ibogaine Formulation IP Portfolio

    10
  11. Apr 24, 2026 · 08:00 · 4151 · Routine +

    Strategic Execution of Global Ziftomenib Pipeline Following US Approval

    Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

    11
  12. Apr 23, 2026 · 21:27 · KNE

    SEDAR Interim Financial Statements

    SEDAR Interim Financial Statements

    12
  13. Apr 23, 2026 · 18:15 · MPH · Routine −

    Cash Burn Accelerates as Medicure Reports 7x Loss Widening Amid Pharmacy Expansion

    Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call

    13
  14. Apr 23, 2026 · 18:00 · ONCO · Neutral

    Onco-Innovations Technical Progress Overshadowed by Severe Capital Dilution and Insider Exits

    Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies

    14
← Newer Older →